Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions.
about
Receptor for advanced glycation end products and its involvement in inflammatory diseasesImpaired vascular-mediated clearance of brain amyloid beta in Alzheimer's disease: the role, regulation and restoration of LRP1The potential of pathological protein fragmentation in blood-based biomarker development for dementia - with emphasis on Alzheimer's diseaseA multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer diseaseNeurovascular pathways to neurodegeneration in Alzheimer's disease and other disordersBridging Type 2 Diabetes and Alzheimer's Disease: Assembling the Puzzle Pieces in the Quest for the Molecules With Therapeutic and Preventive PotentialBrain imaging of neurovascular dysfunction in Alzheimer's disease.Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-β is an early biomarker for mild cognitive impairment preceding Alzheimer's diseaseCerebral amyloid angiopathy in the elderlyLow-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid β-peptide elimination from the brainA lipoprotein receptor cluster IV mutant preferentially binds amyloid-β and regulates its clearance from the mouse brainClearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease.Neurovascular defects and faulty amyloid-β vascular clearance in Alzheimer's diseaseClearing amyloid through the blood-brain barrier.Macromolecules involved in production and metabolism of beta-amyloid at the brain barriers.Low-density lipoprotein receptor-related protein 1: a physiological Aβ homeostatic mechanism with multiple therapeutic opportunities.Blood-brain barrier transport of amyloid beta peptides in efflux pump knock-out animals evaluated by in vivo optical imaging.Deficiency in mural vascular cells coincides with blood-brain barrier disruption in Alzheimer's disease.Cerebral AL lambda-amyloidoma: clinical and pathomorphological characteristics. Review of the literature and of a patient.New therapeutic targets in the neurovascular pathway in Alzheimer's disease.Inflammaging as a prodrome to Alzheimer's diseaseEarly disruptions of the blood-brain barrier may contribute to exacerbated neuronal damage and prolonged functional recovery following stroke in aged ratsThe role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease.Neuronal receptors as targets for the action of amyloid-beta protein (Aβ) in the brain.Expression and function of APP and its metabolites outside the central nervous system.Targeting ApoE4/ApoE receptor LRP1 in Alzheimer's disease.Age-Dependent Regulation of the Blood-Brain Barrier Influx/Efflux Equilibrium of Amyloid-β Peptide in a Mouse Model of Alzheimer's Disease (3xTg-AD).Pharmacological modulation of dietary lipid-induced cerebral capillary dysfunction: Considerations for reducing risk for Alzheimer's disease.A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice.Modeling effect of a γ-secretase inhibitor on amyloid-β dynamics reveals significant role of an amyloid clearance mechanism.APP/Aβ structural diversity and Alzheimer's disease pathogenesis.The effect of exogenous cholesterol and lipid-modulating agents on enterocytic amyloid-beta abundance.Age-associated changes in the blood-brain barrier: comparative studies in human and mouse.Aging alters mRNA expression of amyloid transporter genes at the blood-brain barrier.Differential effects of dietary fatty acids on the cerebral distribution of plasma-derived apo B lipoproteins with amyloid-beta.PPARγ agonist pioglitazone reverses memory impairment and biochemical changes in a mouse model of type 2 diabetes mellitus.Reduction of Blood Amyloid-β Oligomers in Alzheimer's Disease Transgenic Mice by c-Abl Kinase Inhibition.Three-dimensional colocalization analysis of plasma-derived apolipoprotein B with amyloid plaques in APP/PS1 transgenic mice.Anticoagulants inhibit proteolytic clearance of plasma amyloid beta.Hypertension impairs neurovascular coupling and promotes microvascular injury: role in exacerbation of Alzheimer's disease.
P2860
Q21285070-B498983D-CEA4-4E16-9A18-E110951C1009Q26800063-0E5029A7-36B1-4CC1-8C54-EAAE0523B23FQ26853347-769580E3-17A1-47EE-905F-6B96E50F8493Q28261647-80294EB4-7AB4-40B8-9F38-CA7F70F87F04Q29615839-8FA6302D-D852-44EC-B765-635781D05BA7Q29994589-6E7DC682-EE03-4B02-A6BE-5062891B6861Q31066988-C5339066-251E-4B99-B26C-87F974E3FEC9Q33895840-88FEBAD8-694E-4EFF-BAFD-CEF11112D644Q34108298-55545E03-C501-4D55-9057-FCD7D542323BQ34274025-855C900B-6A36-4792-98E8-500F8933983BQ34666433-9FAFEC41-0AAA-412C-B927-8F8D50E2303BQ34960461-62B4CA1F-C690-4EC2-9586-6886A60732F7Q35559895-10C1CCCD-9EE9-4537-AD4E-33607A909350Q35771708-11A1649C-BCF7-493A-9B91-AF8E45951EB1Q35946613-BD0CBC5E-1F1B-4BC8-8B92-ABA5CC508FE6Q36205039-65F5006D-BB57-4BE5-A774-5F78C79FCB6AQ36694561-31E0404D-7EE5-48B5-B38F-09C61C0D23EEQ36773984-0DA8728A-C60B-42A2-9810-68E427FC51CCQ36799367-51EB83CE-6220-4A89-A0CD-125785B2D77DQ36876341-304F13B2-8C4C-45BD-9614-F4321B4B3E1BQ37041389-2B700D07-E7CB-439D-9ABA-EAD9B0F0DB8FQ37195445-44BF5A4C-B329-4A23-AF76-17316B1E2179Q37232866-1C0EC912-B623-401E-962C-258AD3BBD05FQ37977251-1F972942-2688-4120-8A54-26744DE96FD3Q38030678-ADFA077C-DDE2-4BE4-AB3D-76F760CD9A11Q38097859-063DB43D-0A59-41A8-8B45-295B9E6D9870Q38295848-EDB53183-F377-418B-8F26-F536D1942349Q38672178-7ED0DC77-7ED3-4424-A29C-187B185C1FF2Q38784401-CC0B0B8F-6E9F-45BC-873D-CE2376F57129Q44115983-498E8D77-E5FA-430B-92A5-170873C2001EQ46320596-2285BFDB-7A27-4138-BED7-2ED833709FD1Q46480774-7C35953E-D01A-477B-B0ED-9F67262D1C97Q48217866-8DD249E0-7814-4C9A-905B-735761DFD7C7Q48222289-8C124E7E-5702-421C-9659-14D4210BFF4BQ48423106-995DFB52-2C97-474A-A5FC-C8E0F633B69CQ48497036-23BBD5AD-E112-4640-BA12-A817D7C1ABA0Q48547723-1743763D-D856-4D57-B08C-CE888525A068Q48738066-2EA42DD6-2617-4194-A655-FE721992EB74Q49787919-FB2F83E5-75E4-42A5-9FE4-1DA54BFAB955Q54192569-4C2B2931-A0C2-4118-836E-944FD849F3D0
P2860
Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Circulating amyloid-beta pepti ...... o Alzheimer's disease lesions.
@en
Circulating amyloid-beta pepti ...... o Alzheimer's disease lesions.
@nl
type
label
Circulating amyloid-beta pepti ...... o Alzheimer's disease lesions.
@en
Circulating amyloid-beta pepti ...... o Alzheimer's disease lesions.
@nl
prefLabel
Circulating amyloid-beta pepti ...... o Alzheimer's disease lesions.
@en
Circulating amyloid-beta pepti ...... o Alzheimer's disease lesions.
@nl
P2093
P1476
Circulating amyloid-beta pepti ...... o Alzheimer's disease lesions.
@en
P2093
Berislav V Zlokovic
Blas Frangione
James Bading
Jasmina B Mackic
Jorge Ghiso
Larry Walker
P304
P356
10.1016/S1537-1891(02)00198-2
P577
2002-06-01T00:00:00Z